Early trial tests nanoparticle therapy to help celiac patients tolerate gluten
Disease control
Recruiting now
This is the first human trial testing VTP-1000, a new nanoparticle-based therapy for celiac disease. The study aims to see if the treatment is safe and can help the immune system tolerate gluten, potentially reducing the body's harmful reaction. It will involve 45 adults with cel…
Phase: EARLY_PHASE1 • Sponsor: Barinthus Biotherapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC